<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2382">
  <stage>Registered</stage>
  <submitdate>28/05/2009</submitdate>
  <approvaldate>28/05/2009</approvaldate>
  <nctid>NCT00911508</nctid>
  <trial_identification>
    <studytitle>Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial</studytitle>
    <scientifictitle>Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial</scientifictitle>
    <utrn />
    <trialacronym>CABANA</trialacronym>
    <secondaryid>U01HL089709</secondaryid>
    <secondaryid>09-004616</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Atrial Fibrillation</healthcondition>
    <healthcondition>Arrhythmia</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Left atrial ablation
Treatment: drugs - Rate or Rhythm Control Therapy

Active Comparator: Left Atrial Ablation - Pulmonary vein isolation using a circumferential ablative approach in the left atrium. Ablation may be performed using circular mapping catheter-guided ablation, antral isolation using a circular guided approach, or wide area circumferential ablation.

Active Comparator: Rate or Rhythm Control Therapy - Current state-of-the-art drug therapy for atrial fibrillation (rate control or rhythm control). Treating physicians will be encouraged to follow the American College of Cardiology / American Heart Association / European Society of Cardiology Atrial Fibrillation Guidelines with regard to drug therapy for atrial fibrillation. The specific choice of rate control versus rhythm control drug therapy and the specific drugs to be used will ultimately be left to the discretion of the treating physician.


Treatment: devices: Left atrial ablation
St. Jude: Livewire TC , Therapy Dual / Thermocouple, Safire,Therapy Cool Path
Biosense Webster: NAVI-STAR, NAVI-STAR/NAVI-STAR DS, Celsius Braided/Long Tip, NAVI-STAR and Celsius ThermoCool, NAVI-STAR® RMT, Celsius® RMT, ThermoCool® SF
Medtronic CryoCath LP: Freezor®/Freezor MAX®, Artic Front®, Cardiac Ablation System
Bard: Stinger
Boston Scientific: Blazer II RF/XP, Blazer RPM, Chilli II Cooled, SteeroCath

Treatment: drugs: Rate or Rhythm Control Therapy
Rate control: Metoprolol 50-100mg, Atenolol 50-100mg, Propranolol 40-80mg, Acebutolol 200-300mg, Carvedilol 6.25-25mg, Diltiazem 180-240mg, Verapamil 180-240mg, Digoxin 0.125-0.25mg
Rhythm control: Propafenone 450-625mg, Flecainide 200-300mg, Sotalol 240-320mg, Dofetilide 500-1000mcg, Amiodarone 200-400mg, Quinidine 600-900mg, Dronedarone 800mg

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>LA catheter ablation is superior to rate or rhythm control drug therapy for decreasing the incidence of the composite endpoint of total mortality, disabling stroke, serious bleeding, or cardiac arrest in patients warranting therapy for AF.</outcome>
      <timepoint>From date of enrollment until date of event</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>LA catheter ablation is superior to rate or rhythm control drug therapy for reducing total mortality</outcome>
      <timepoint>From date of enrollment until date of death</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total mortality or cardiovascular hospitalization</outcome>
      <timepoint>From date of enrollment until date of death or CV hospitalization</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiovascular death</outcome>
      <timepoint>From date of enrollment until date of death</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiovascular death or disabling stroke</outcome>
      <timepoint>From date of enrollment until date of event</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Arrhythmic death or cardiac arrest</outcome>
      <timepoint>From date of enrollment until date of event</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Heart failure death</outcome>
      <timepoint>From date of enrollment until date of event</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Freedom from recurrent AF</outcome>
      <timepoint>From date of therapy initiation until date of first AF recurrence following a 90 day wait period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiovascular hospitalization</outcome>
      <timepoint>From date of enrollment until date of hospitalization</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Medical costs, resource utilization, and cost effectiveness</outcome>
      <timepoint>From date of enrollment through follow-up (average of 5 years)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life</outcome>
      <timepoint>At months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Composite adverse events</outcome>
      <timepoint>From date of enrollment until date of event</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Left atrial size, morphology and function and its relationship to morbidity and mortality</outcome>
      <timepoint>Baseline compared with 3-6 months post therapy initiation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Over the preceding 6 months have:

               1. =2 paroxysmal (electrocardiographic documentation of at least 1) AF episodes
                  lasting =1 hour in duration: (that terminate spontaneously within 7 days or
                  cardioversion is performed within 48h of AF onset): or

               2. electrocardiographic documentation of 1 persistent AF episode: (sustained for =7
                  days or cardioversion is performed more than 48h after AF onset): or

               3. electrocardiographic documentation of 1 longstanding persistent AF episode:
                  (continuous AF of duration &gt;1 year).

          -  Warrant active therapy (within the past 3 months) beyond simple ongoing observation

          -  Be eligible for catheter ablation and =2 sequential rhythm control and/or =2 rate
             control drugs.

          -  Be =65 yrs of age, or &lt;65 yrs with one or more of the following risk factors for
             stroke: Hypertension (treated and/or defined as a BP &gt;140/90 mmHg) [90], Diabetes
             (treated and/or defined as a fasting glucose =126 mg/dl) [91], Congestive heart
             failure (including systolic or diastolic heart failure), Prior stroke, TIA or systemic
             emboli, Atherosclerotic vascular disease (previous MI, peripheral arterial disease or
             aortic plaque), LA size &gt;5.0 cm (or volume index =40 cc/m2), or EF =35.

          -  Have the capacity to understand and sign an informed consent form.

          -  Be =18 years of age.

               -  NOTE- Subjects &lt;65 yrs of age whose only risk factor is hypertension must have a
                  second risk factor or LV hypertrophy to qualify.Patients receiving new drug
                  therapy initiated within the previous 3 months may continue that therapy if
                  randomized to the drug therapy arm. Patients may have documented atrial flutter
                  in addition to atrial fibrillation and remain eligible for enrollment.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Lone AF in the absence of risk factors for stroke in patients &lt;65 years of age

          -  Patients who in the opinion of the managing clinician should not yet receive any
             therapy for AF

          -  Patients who have failed &gt;2 membrane active anti-arrhythmic drugs at a therapeutic
             dose due to inefficacy or side effects (Table 5.2.2)

          -  An efficacy failure of full dose amiodarone treatment &gt;8 weeks duration at any time

          -  Reversible causes of AF including thyroid disorders, acute alcohol intoxication,
             recent major surgical procedures, or trauma

          -  Recent cardiac events including MI, PCI, or valve or bypass surgery in the preceding 3
             months

          -  Hypertrophic obstructive cardiomyopathy (outflow track)

          -  Class IV angina or Class IV CHF (including past or planned heart transplantation)

          -  Other arrhythmias mandating anti-arrhythmic drug therapy (i.e. VT, VF)

          -  Heritable arrhythmias or increased risk for torsade de pointes with class I or III
             drugs

          -  Prior LA catheter ablation with the intention of treating AF

          -  Prior surgical interventions for AF such as the MAZE procedure

          -  Prior AV nodal ablation

          -  Patients with other arrhythmias requiring ablative therapy

          -  Contraindication to appropriate anti-coagulation therapy

          -  Renal failure requiring dialysis

          -  Medical conditions limiting expected survival to &lt;1 year

          -  Women of childbearing potential (unless post-menopausal or surgically sterile)

          -  Participation in any other clinical mortality trial (Participation in other
             non-mortality trials should be reviewed with the clinical trial management center)

          -  Unable to give informed consent

               -  NOTE- Prior ablation of the cavo-tricuspid isthmus alone is not an exclusion if
                  the patient develops subsequent recurrent AF. Planned atrial flutter ablation in
                  combination with the left atrial ablation is not an exclusion.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>2204</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC</recruitmentstate>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3050 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Guangdong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Jiangsu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Liaoning</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Hlavni Mesto Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Prague 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Prague 4</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-Wurttemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bayern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freie-Hansestadt Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nordrhein-Westfalen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Saxony</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Nauheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gottingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Karlsruhe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rostock</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Varese</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Novosibirskaya Oblast</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Tomsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Mayo Clinic</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Heart, Lung, and Blood Institute (NHLBI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>St. Jude Medical</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Biosense Webster, Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The (Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial)
      CABANA Trial has the overall goal of establishing the appropriate roles for medical and
      ablative intervention for atrial fibrillation (AF). The CABANA Trial is designed to test the
      hypothesis that the treatment strategy of left atrial catheter ablation for the purpose of
      eliminating atrial fibrillation (AF) will be superior to current state-of-the-art therapy
      with either rate control or rhythm control drugs for decreasing the incidence of the
      composite endpoint of total mortality, disabling stroke, serious bleeding, or cardiac arrest
      in patients with untreated or incompletely treated AF.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00911508</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Douglas L. Packer, M.D.</name>
      <address>Mayo Clinic</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>